



BC Centre for Disease Control
An agency of the Provincial Health Services Authority

Immunization Programs and Vaccine
Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: April 1, 2015 Administrative Circular: 2015:03

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program, Section VII – Biological Products**

Section VII – Biological Products

Measles-Mumps-Rubella Vaccine

Updated footnotes to indicate that individuals born prior to 1970 who self-identify without a history of measles or mumps vaccine or disease should be offered 1 dose of MMR vaccine.

Please remove page numbers: 35a-35d dated September 2014

Please add new page numbers: 35a-35d dated March 2015

Pneumococcal Conjugate Vaccine (Pevnar®13)

New indication added for children and adults with HIV infection based on the recent National Advisory Committee on Immunization (NACI) statement. Indications section reformatted and updated to include “HSCT recipients”, and “Anatomic or Functional Asplenia to 18 years of age (inclusive)”. The upper age indication for those with anatomic or functional asplenia has changed from 16 years to 18 years.

Content added regarding “Recommended by the National Advisory Committee on Immunization but Not Provided Free in BC”.

Content added to ‘Doses and Schedules’ and ‘Precautions’ regarding timing of administration of pneumococcal conjugate and polysaccharide vaccines.

Removed precaution related to febrile seizures in children following concomitant administration of PCV13 and trivalent influenza vaccine. Febrile seizures have been included under ‘Adverse Events’.

Adverse Events updated to include information for those 5 years of age and older.

Page 1 of 3

Completing a Pneumococcal Conjugate Vaccine Series

The content and date on this page have not been changed but the page has been renumbered.

Recommendations for Pneumococcal Immunization with 13-Valent Pneumococcal Conjugate Vaccine (PCV 13) and 23-Valent Pneumococcal Polysaccharide Vaccine (PPV 23) for Children at High Risk of Pneumococcal Disease

This page has been removed as the content is covered in the product pages.

Pneumococcal Polysaccharide Vaccine (Pneumo 23®)

These pages have been removed as this product is not currently available in Canada.

Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

Content added to 'Doses and Schedules' regarding timing of administration of PCV13 and PPV23.

Revised the recommendations for the once-only re-vaccination dose for those at highest risk of IPD based on the recent NACI statement. Re-vaccination should now occur 5 years after the initial dose **for all ages**. This is a change in the interval for re-vaccination for children initially vaccinated at 10 years of age and younger, where re-vaccination was previously recommended 3 years after the initial dose. HSCT recipients have also been added to those eligible for re-vaccination (see Section III-Immunization of Special Populations for details on timing of re-vaccination).

Moved content from footnote related to concomitant administration of PPV23 and Zostavax® under 'Administration'. Content pertaining to co-administration of PPV23 and other vaccines was removed.

Removed specific information regarding Hodgkin's disease and chemotherapy as this is applicable to all vaccines and is addressed in Section III-Immunization of Special Populations. The following content has been included under 'Precautions':
"Pneumococcal vaccination should be administered at least two weeks prior to the initiation of immunosuppressive therapy."

**Please remove page numbers: 44-50 dated between January 2010-January 2012.
Please insert page numbers: 44-46 dated March 2015, page 47 dated November 2010 and pages 48-50 dated March 2015.**

Please also remove the Table of Contents for Section VII – Biologicals Products dated October 2014 and replace with the enclosed updated Table of Contents dated March 2015.

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at Christine.halpert@bccdc.ca.

Sincerely,



Monika Naus, MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Dr. Evan Adams
Deputy Provincial Health Officer for Aboriginal Health

Craig Thompson
Director, CD Prevention – Immunization

Warren O'Brian
Executive Director,
Communicable Disease and Addiction Prevention